Experimental cell therapy takes aim at Hard-to-Treat autoimmune diseases

NCT ID NCT07526493

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the faulty immune cells causing the disease. Only 6 participants will be enrolled to check for safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QH103 cell injection (genetically modified immune cells targeting CD19)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases that attack the nervous system.
What could go wrong: This is a very early, small phase 1 trial with only 6 participants, so safety and effectiveness are not yet known. There are risks of serious side effects like cytokine release syndrome or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN IMMUNOGLOBULIN G ANTIBODY-ASSOCIATED DISEASE (MOGAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy autoimmune disorder of the nervous system autoimmune encephalitis chronic inflammatory demyelinating polyradiculoneuropathy multiple sclerosis myasthenia gravis myelin oligodendrocyte glycoprotein antibody-associated disease myositis disease neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN IMMUNOGLOBULIN G ANTIBODY-ASSOCIATED DISEASE (MOGAD) AUTOIMMUNE ENCEPHALITIS (AE) CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IDIOPATHIC INFLAMMATORY MYOPATHIES(IIM) MULTIPLE SCLEROSIS, MS MYASTHENIA GRAVIS (MG) NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.